CA19.9 antigen circulating in the serum of colon cancer patients: Where is it from?

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 4, 2013, Pages 792-797

  Mare, Lydia ^a   Caretti, Anna ^b   Albertini, Riccardo ^c   Trinchera, Marco ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Carbohydrate antigen; Colon cancer; Gastrointestinal tract; Hepatobiliary system; Tumor marker

Indexed keywords

BETA 1,3 GALACTOSYLTRANSFERASE; CA 19-9 ANTIGEN; GALACTOSYLTRANSFERASE; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BIOSYNTHESIS; CANCER PATIENT; CELL SURFACE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL;

ADENOCARCINOMA; CA-19-9 ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GALACTOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; OLIGOSACCHARIDES; RNA, MESSENGER;

EID: 84873480086     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.01.004     Document Type: Article

References (36)

1. M. Akdoǧan, N. Saşmaz, B. Kayhan, I. Biyikoǧlu, S. Dişibeyaz, and B. Sahin Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature Tumori 87 2001 337 339
2. D. Baeckström, G.C. Hansson, O. Nilsson, C. Johansson, S.J. Gendler, and L. Lindholm Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins Journal of Biological Chemistry 266 1991 21537 21547
3. D. Baeckström, N. Karlsson, and G.C. Hansson Purification and characterization of sialyl-Le(a)-carrying mucins of human bile; evidence for the presence of MUC1 and MUC3 apoproteins Journal of Biological Chemistry 269 1994 14430 14437
4. D. Baeckström, K. Zhang, N. Asker, U. Rüetschi, M. Ek, and G.C. Hansson Expression of the leukocyte-associated sialoglycoprotein CD43 by a colon carcinoma cell line Journal of Biological Chemistry 270 1995 13688 13692
5. U.K. Ballehaninna, and R.S. Chamberlain The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal Journal of Gastrointestinal Oncology 3 2012 105 119
6. A. Bardoni, M. Valli, and M. Trinchera Differential expression of beta1,3galactosyltransferases in human colon cells derived from adenocarcinomas or normal mucosa FEBS Letters 451 1999 75 80
7. P. Byström, A. Berglund, P. Nygren, L. Wernroth, B. Johansson, A. Larsson, and B. Glimelius Evaluation of predictive markers for patients with advanced colorectal cancer Acta Oncologica 51 2012 849 859
8. A. Caretti, S.M. Sirchia, S. Tabano, A. Zulueta, F. Dall'Olio, and M. Trinchera DNA methylation and histone modifications modulate the β1,3 galactosyltransferase β3Gal-T5 native promoter in cancer cells International Journal of Biochemistry & Cell Biology 44 2012 84 90
9. F. Dall'Olio, N. Malagolini, M. Trinchera, and M. Chiricolo Mechanisms of cancer-associated glycosylation changes Frontiers in Bioscience 17 2012 670 699
10. R.J. de Haas, D.A. Wicherts, E. Flores, M. Ducreux, F. Lévi, and B. Paule Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases Annals of Surgical Oncology 17 2010 1010 1023
11. M.J. Duffy, A. van Dalen, C. Haglund, L. Hansson, R. Klapdor, and R. Lamerz Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines European Journal of Cancer 39 2003 718 727
12. M.J. Duffy, A. van Dalen, C. Haglund, L. Hansson, E. Holinski-Feder, and R. Klapdor Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use European Journal of Cancer 43 2007 1348 1360
13. M.J. Duffy, C. Sturgeon, R. Lamerz, C. Haglund, V.L. Holubec, and R. Klapdor Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report Annals of Oncology 21 2010 441 447
14. S. Isshiki, T. Kudo, S. Nishihara, Y. Ikehara, A. Togayachi, and A. Furuya Lewis type 1 antigen synthase (beta3Gal-T5) is transcriptionally regulated by homeoproteins Journal of Biological Chemistry 278 2003 36611 36620
15. H. Ito, N. Hiraiwa, M. Sawada-Kasugai, S. Akamatsu, T. Tachikawa, and Y. Kasai Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues International Journal of Cancer 71 1997 556 564
16. S. Kikkawa, K. Sogawa, M. Satoh, H. Umemura, Y. Kodera, and K. Matsushita Identification of a novel biomarker for biliary tract cancer using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry International Journal of Proteomics 2012 2012 108609
17. D.H. Kim, S.J. Oh, C.A. Oh, M.G. Choi, J.H. Noh, and T.S. Sohn The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy Journal of Surgical Oncology 104 2011 585 591
18. T. Kudo, Y. Ikehara, A. Togayachi, K. Morozumi, M. Watanabe, and M. Nakamura Up-regulation of a set of glycosyltransferase genes in human colorectal cancer Laboratory Investigation 78 1998 797 811
19. P.C. Lin, J.K. Lin, C.C. Lin, H.S. Wang, S.H. Yang, and J.K. Jiang Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis International Journal of Colorectal Disease 27 2012 1333 1338
20. G.Y. Locker, S. Hamilton, J. Harris, J.M. Jessup, N. Kemeny, and J.S. Macdonald ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer Journal of Clinical Oncology 24 2006 5313 5327
21. J.L. Magnani, Z. Steplewski, H. Koprowski, and V. Ginsburg Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin Cancer Research 43 1983 5489 5492
22. D.V. Mann, R. Edwards, and S. Ho Lau WY, and Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice European Journal of Surgical Oncology 26 2000 474 479
23. L. Mare, and M. Trinchera Suppression of β 1,3galactosyltransferase β3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans European Journal of Biochemistry 271 2004 186 194
24. P. Maxwell Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker British Journal of Biomedical Science 1999 209 214
25. Y. Misonou, K. Shida, H. Korekane, Y. Seki, S. Noura, M. Ohue, and Y. Miyamoto Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells Journal of Proteome Research 8 2009 2990 3005
26. T. Nakagoe, T. Sawai, T. Tsuji, M. Jibiki, M. Ohbatake, and A. Nanashima Differences in release mechanisms and distributions for sialyl Le(a) and sialyl Le(x) antigens in colorectal cancer Annals of Surgical Oncology 7 2000 289 295
27. H. Narimatsu, H. Iwasaki, F. Nakayama, Y. Ikehara, T. Kudo, and S. Nishihara Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients Cancer Res. 58 1998 512 518
28. R. Salvini, A. Bardoni, M. Valli, and M. Trinchera Beta 1,3-Galactosyltransferase beta 3Gal-T5 acts on the GlcNAcbeta 1→3Galbeta 1→4GlcNAcbeta 1→R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas Journal of Biological Chemistry 276 2001 3564 3573
29. A. Seko, T. Ohkura, H. Kitamura, S. Yonezawa, E. Sato, and K. Yamashita Quantitative differences in GlcNAc: beta1→3 and GlcNAc:beta1→4 galactosyltransferase activities between human colonic adenocarcinomas and normal colonic mucosa Cancer Research 56 1996 3468 3473
30. Y. Tabuchi, H. Deguchi, and Y. Saitoh Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables Cancer 62 1988 1605 1613
31. M. Trinchera, N. Malagolini, M. Chiricolo, D. Santini, F. Minni, A. Caretti, and F. Dall'olio The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach International Journal of Biochemistry and Cell Biology 43 2011 130 139
32. M. Valli, A. Gallanti, S. Bozzaro, and M. Trinchera Beta-1,3- galactosyltransferase and alpha-1,2-fucosyltransferase involved in the biosynthesis of type-1-chain carbohydrate antigens in human colon adenocarcinoma cell lines European Journal of Biochemistry 256 1998 494 501
33. P.P. van der Veek, W.H. de Vos Tot Nederveen Cappel, A.M. Langers, and B. van Hoek Two patients with extremely elevated tumor markers: where is the malignancy? Gastroenterology Research and Practice 2011 2011 123743
34. K. Yamashita, and M. Watanabe Clinical significance of tumor markers and an emerging perspective on colorectal cancer Cancer Science 100 2009 195 199
35. T. Yue, K.A. Maupin, B. Fallon, L. Li, K. Partyka, and M.A. Anderson Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers PLoS ONE 6 2011 e29180
36. T. Yue, K. Partyka, K.A. Maupin, M. Hurley, P. Andrews, and K. Kaul Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases Proteomics 11 2011 3665 3674